Application

18488169 · BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment

Filed 2023-10-17 · Abandoned The official file ↗ · Art unit 1628 · Examiner Theodore R Howell Typical · CPC A61K 31/519 · Acerta Pharma B.V. · Morgan, Lewis & Bockius LLP (Acerta)

Office actions

first was Non-final rejection

RCEs

no appeal

To first action

26.7 mo

to disposition 33.9 mo

Statutes raised

102 103 112 DP

1 actions read

Unlock the prosecution timelineIncluded in Pro, from $29 a month. Cancel any time.